James Paton

Page 3 of 3

  • Sanofi will combine its experimental coronavirus vaccine with GlaxoSmithKline Plc’s adjuvant technology, which may allow more doses of a shot to be produced.Health

    Sanofi and GlaxoSmithKline are teaming up to develop a coronavirus vaccine

    By James Paton, Suzi Ring, and others
  • A researcher works on virus replication in order to develop a vaccine against the coronavirus COVID-19, in Belo Horizonte, state of Minas Gerais, Brazil, on March 26, 2020. - The Ministry of Health convened The Technological Vaccine Center of the Federal University of Minas Gerais laboratory to conduct research on the coronavirus COVID-19 in order to diagnose, test and develop a vaccine. (Photo by Douglas MAGNO / AFP) (Photo by DOUGLAS MAGNO/AFP via Getty Images)Health

    A coronavirus vaccine in 18 months? Medical experts say it’s not that simple

    By James Paton and Bloomberg
  • New British Chief Executive Officer of French pharmaceutical group Sanofi Paul Hudson talks to journalists at Sanofi headquarters in Paris on October 1, 2019. (Photo by ERIC PIERMONT / AFP) (Photo by ERIC PIERMONT/AFP via Getty Images)International

    Why Sanofi’s New CEO Is Trading Diabetes Drugs for Cancer Breakthroughs

    By James Paton and Bloomberg
  • Merck, which makes Keytruda, will acquire ArQule, which develops kinase inhibitors, and Sanofi, the French drug giant, agreed to buy Synthorx, which is developing drugs including immunotherapies.Health

    Cancer Drug Company Acquisitions Showcase Pharma Giants Big Push Into Oncology

    By Riley Griffin, James Paton, and others
  • Paul Hudson, chief executive officer of Sanofi, gestures as he speaks during a panel session on the sidelines of the China International Import Expo (CIIE) in Shanghai, China, on Tuesday, Nov. 5, 2019. The CIIE -- now in its second year -- is designed to showcase the countrys desire to shift its economy toward consumption by buying more foreign goods. Photographer: Qilai Shen/Bloomberg via Getty ImagesInternational

    Why Sanofi Is Buying a U.S. Cancer Biotech for Nearly 3 Times Its Market Value

    By James Paton and Bloomberg
  • American Vasant Narasimhan, CEO of Swiss pharmaceutical and drug maker Novartis speaks during a conference at the Fortune Global Forum event in Paris on Nov. 18, 2019. (Photo by ERIC PIERMONT / AFP) (Photo by ERIC PIERMONT/AFP via Getty Images)International

    Novartis Bets Big on Cholesterol Drug With $9.7 Billion Buyout of Medicines Co.

    By James Paton and Bloomberg